Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Target Price of $66.00 According to Analysts

Key Points

• Analyst sentiment is bullish: Twenty-one brokerages give Definium Therapeutics a consensus “Moderate Buy” rating, with 19 buys, one strong buy, and one sell. The average 12-month price target is $66, versus a recent opening price of $35.49.
• Recent earnings missed expectations: Definium reported a quarterly loss of $1.44 per share, wider than the consensus loss estimate of $0.55. Analysts expect a full-year loss of approximately $3.08 per share.
• Insiders have been selling shares: Company insiders sold 71,098 shares worth about $2.63 million over the past 90 days, while institutional investors own 27.91% of the stock. The company is developing MM120 and DT402 for brain health disorders, including anxiety, ADHD, and autism-related conditions.

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-one brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $66.00.

A number of equities analysts have issued reports on the company. Wells Fargo & Company lifted their price target on Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a research note on Thursday, August 13th. Stifel Nicolaus raised their target price on Definium Therapeutics from $30.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. JonesTrading lifted their target price on Definium Therapeutics from $74.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, Maxim Group set a $55.00 price target on Definium Therapeutics and gave the stock a "buy" rating in a report on Friday, August 14th.

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $35.49 on Thursday. The company has a fifty day simple moving average of $38.78 and a 200 day simple moving average of $33.95. Definium Therapeutics has a 12-month low of $10.46 and a 12-month high of $49.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The company has a market cap of $4.77 billion, a P/E ratio of -10.35 and a beta of 2.19.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Sell-side analysts predict that Definium Therapeutics will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Sullivan sold 14,051 shares of the firm's stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $513,845.07. Following the transaction, the insider directly owned 494,228 shares of the company's stock, valued at $18,073,917.96. This trade represents a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew Wiley sold 3,097 shares of the business's stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the transaction, the insider owned 359,036 shares in the company, valued at approximately $13,129,946.52. This trade represents a 0.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 71,098 shares of company stock valued at $2,626,115 in the last 90 days. Insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company's stock worth $59,000 after purchasing an additional 343 shares during the last quarter. TD Waterhouse Canada Inc. increased its position in shares of Definium Therapeutics by 1.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 37,147 shares of the company's stock valued at $1,396,000 after purchasing an additional 453 shares during the last quarter. Nykredit A S purchased a new stake in shares of Definium Therapeutics during the 2nd quarter valued at $45,000. Nisa Investment Advisors LLC increased its position in shares of Definium Therapeutics by 2.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 49,607 shares of the company's stock valued at $1,888,000 after purchasing an additional 1,238 shares during the last quarter. Finally, Allworth Financial LP bought a new stake in shares of Definium Therapeutics during the 2nd quarter worth $110,000. Institutional investors own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.